Ian Thomas Lund PA PA-C

Physician Assistant

Elm and Carlton StreetsBuffalo, NY 14263
Phone+1 716-845-2300

Ian Thomas Lund is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Ian Lund's full profile Already have an account?

Summary

Ian Lund is a Physician Assistant specializing in Oncology based in Buffalo, NY. He completed his education at Daemen College in 2010 and since then, has been employed at Roswell Park Comprehensive Cancer Center.

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

National Commission on Certification of Physician Assistants (NCCPA) Certified Physician Assistant

Education & Training

Daemen CollegePhysician Assistant, 2010

Professional Memberships

American Academy of Physician Assistants - AAPA
Member

Publications & Presentations

PubMed

40 citations
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
Othman S. Akhtar, Kris Attwood, Ian Lund, Ryan Hare, Francisco J. Hernandez-Ilizaliturri
Leukemia & Lymphoma. 2019-01-02

Journal Articles

P831: Novel immunosuppressive myeloid populations in the bone marrow and osteolytic lesions of Multiple Myeloma patients.
Hillengass J, Lannes R, Daneshmandi S, MacDonald C, Yan Qi, Choi J, Singh Prashant, Belal A, Alberico Ronald, Lund, I, Schaefer M, Parker Sarah, Munshi Nikhil, Anderso..., Hemasphere, 8/2023
Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma
Shalaby K, Carlson L, Celotto K, Chavel C, Lund I, McCaffrey K, Schaefer M, Dupuis M, Hillengass K, Lee K., J Clin Onc, 6/2023
P. Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.
Akhtar OS, Groman A, Singh A, Ghione P, Lund I, Hernandez-Ilizaliturri FJ, Torka P, Leuk Lymphoma, 5/2022

Abstracts/Posters

Impact of social determinants of health on survival outcomes in Multiple Myeloma patients at a major cancer center.
Alharbi M, Abdalla E, Bawek S, Forbes C, Lund I, Yu H, Durand B, Hillengass J, Hassan H., ASH 2024
Effects of Dose reductions of Lenalidomide given as maintenance following autologous stem cell transplant in patients with Multiple Myeloma.
Lund I, Azad F, Attwood K, George, A, Hillengass, J., ASH 2023